Gilead must face pay-for-delay suit
Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Chugai settles cancer drug patent dispute with US firm
Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.
Pharma unit could get green light to launch IBS generic
Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
ViiV Healthcare signs deal to boost HIV drug access
Pharma firm joins with patent pool to expand access to HIV treatment | 90 countries set to benefit from preventative medicine
Competition watchdog fines big pharma duo £70m
The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.
Generic maker pays $145m to settle antitrust suit
California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.
Teva takes long-running ‘skinny label’ suit to SCOTUS
Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Federal Circuit rejects ADHD generic drug challenge
A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
USPTO and FDA unite to tackle drug pricing
The US Patent and Trademark Office and Food and Drug Administration have partnered to facilitate access to affordable drugs.
English High Court rejects second injunction bid over melatonin medicine
Justice Mellor was unconvinced by arguments that Teva could have cleared the way.